The 340B Drug Pricing Program lawsuit filed on 9 October 2026 asks a federal court to stop a federal rebate model that hospitals say would cost them more than $1 billion a year. The American Hospital Association (AHA) said it and other plaintiffs sued in the US District Court for the District of Maine to block changes to the 340B programme before they are due to start on 1 January 2027.
The case is a second round in a fight that has already reached an appeals court. This report sets out what the suit challenges, how the 340B rebate program 2026 plan works, why the cost estimates differ so widely, and what could happen next.
340B Drug Pricing Program lawsuit: key points
- Filed: 9 October 2026, US District Court for the District of Maine.
- Plaintiffs: the American Hospital Association, the Maine Hospital Association and safety-net providers.
- Target: a rebate model under which upfront 340B discounts would be replaced by after-the-sale rebates.
- Start date being challenged: 1 January 2027.
- Cost dispute: the AHA cites more than $1 billion a year in new administrative costs; the government estimate is $537.2 million a year.
What the 340B Drug Pricing Program lawsuit is about
The 340B Drug Pricing Program requires drugmakers to sell outpatient drugs at reduced prices to certain safety-net hospitals and clinics. Hospitals keep the difference between the discounted purchase price and what insurers pay, and they say they use that margin to fund care for low-income and rural patients. The Health Resources and Services Administration (HRSA) runs the programme.
The programme has grown quickly. One report puts purchases at a record $66.3 billion in 2023, up more than 50% from $43.9 billion two years earlier, and says about 3,000 hospitals benefit. A later report says purchases passed $100 billion in 2025. By our calculation, the first pair of figures is a rise of about 51%. The two sets of figures may not measure exactly the same thing, so we do not compare them directly.
The 340B rebate program 2026 plan at the centre of the 340B Drug Pricing Program lawsuit
Today, hospitals get the 340B discount when they buy a drug. Under the rebate model, they would pay more at purchase and then claim a rebate from the manufacturer afterwards. Supporters of the model say it would help stop drugmakers paying duplicate discounts on the same drug and would improve oversight. Hospitals say it would tie up cash and force them to run a heavy claims process.
The second version of the plan, according to one report, covers 21 drugs and 10 manufacturers. The AHA describes it as twice as large and more expensive than the first. Final guidance from late July added safeguards: manufacturers would build and maintain the IT systems for purchase claims, and any rebate denial must come with documented reasons.
Timeline of the 340B Drug Pricing Program lawsuit
- Summer 2025: HHS announces a first rebate pilot.
- Mid-October 2025: HRSA moves ahead, giving providers about two months to comply.
- 1 December 2025: the AHA, the Maine Hospital Association and other plaintiffs sue.
- 29 December 2025: a federal judge in Maine pauses the pilot, calling it hastily assembled and finding the administrative record thin.
- 7 January 2026: the First Circuit upholds the pause.
- Afterwards: HRSA withdraws the first version and restarts with a longer public comment process.
- 9 October 2026: the new American Hospital Association lawsuit is filed against the revised plan.
What the American Hospital Association lawsuit argues
The complaint seeks declaratory and injunctive relief, meaning a ruling that the programme is unlawful and an order blocking it. Reports quote it as arguing that the rebate programme is arbitrary and capricious and must be set aside, a standard phrase from administrative law. The core claim is that HHS and HRSA ignored feedback on provider costs and on lower-cost alternatives, the same weakness the courts found in the first attempt.
AHA president and chief executive Steve Walsh said: “It’s unfortunate that we are back in court challenging the same flawed program.” The AHA says it proposed alternatives that address transparency and programme integrity at lower cost.
The cost dispute behind the 340B Drug Pricing Program lawsuit
The two estimates are far apart. The AHA puts the new administrative burden on hospitals at more than $1 billion a year. HRSA estimated $537.2 million a year across all covered entities. By our calculation, the AHA figure is about 1.9 times the government’s. Spread across the roughly 3,000 hospitals mentioned above, $1 billion would be about $333,000 each, but that is a crude illustration of ours: the rebate model covers more entities than hospitals alone, and costs would fall unevenly.
Reports do not explain in detail how each side built its number, so readers should treat both as estimates by interested parties. The court record, rather than the press releases, is where the methods will be tested.
What HHS and drugmakers say about the 340B Drug Pricing Program lawsuit
The US Department of Health and Human Services (HHS) has said the 340B programme has expanded beyond its original intent, which it describes as supporting struggling safety-net facilities. Fierce reporting noted that HRSA had not responded to a request for comment on the new suit. Drugmakers have pursued their own rebate models in the past, but courts have ruled that only HHS has the authority to impose such a model, according to the same reports.
Differences between reports on the 340B Drug Pricing Program lawsuit
Accounts differ on who is suing. The AHA names four safety-net hospitals: Eastern Maine Medical Center, Unity Medical Center in North Dakota, Dallas County Medical Center in Arkansas, and Nathan Littauer Hospital and Nursing Home in New York. Another report refers to three community-based providers. The case is titled AHA v. Kennedy, and some reports name HRSA as a defendant as well as HHS. We have not seen the complaint, so we describe the plaintiffs as the AHA, the Maine Hospital Association and safety-net providers.
Why this matters for hospital drug pricing regulations
The case is part of a broader push on hospital drug pricing regulations and US healthcare policy 2026. A separate proposal from the Centers for Medicare & Medicaid Services (CMS) is described in one report as cutting the rate paid for 340B drugs from 6% above average sales price to 33.4% below it, and hospital groups have signalled they will challenge it. We could not confirm the details of that proposal from the sources we reviewed. For related policy coverage, see our reports on states joining the Medicaid international drug-pricing model and on hospital consumable markups in India, or browse more pharmaceutical news.
Our assessment
In our assessment, the 340B Drug Pricing Program lawsuit will turn less on whether rebates are a good idea and more on whether the agency built a proper record. The first court decision rested on process, not on the merits of rebates. HHS has added a longer comment period and more guardrails this time, so the question is whether that is enough. A ruling before 1 January is likely to decide whether the model starts.
What to watch next in the 340B Drug Pricing Program lawsuit
- A hearing date or ruling on a preliminary injunction before 1 January 2027.
- HRSA and HHS responses to the complaint.
- The CMS proposal on payment for 340B drugs and any challenge to it.
- Whether drugmakers sign up for the rebate model.
Frequently asked questions
What is the 340B Drug Pricing Program lawsuit about?
The AHA, the Maine Hospital Association and safety-net providers are suing to stop a federal rebate model for 340B drugs before it starts on 1 January 2027.
How much would the rebate program cost hospitals?
The AHA estimates more than $1 billion a year in new administrative costs. HRSA estimated $537.2 million a year across all covered entities.
Has a court acted before the 340B Drug Pricing Program lawsuit?
Yes. A federal court in Maine paused the first pilot on 29 December 2025, and the First Circuit upheld the pause on 7 January 2026.
What is the 340B Drug Pricing Program?
A federal programme that requires drugmakers to sell outpatient drugs at reduced prices to eligible safety-net hospitals and clinics.
When could the 340B Drug Pricing Program lawsuit stop the rebate model?
On 1 January 2027, unless a court blocks it.
How we reported this: we relied on the AHA announcement of 9 October 2026 and on published reports of the complaint and the earlier litigation. We did not read the complaint. Cost estimates are from interested parties, and figures labelled as ours are our own calculations. Last updated: 10 October 2026. This article is news reporting and not legal or financial advice.